| 48.77 -2.06 (-4.05%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 61.7 | 1-year : | 72.07 |
| Resists | First : | 52.83 | Second : | 61.7 |
| Pivot price | 48.9  |
|||
| Supports | First : | 44.74 | Second : | 39.75 |
| MAs | MA(5) : | 50.52 |
MA(20) : | 47.53 |
| MA(100) : | 40 |
MA(250) : | 32.51 |
|
| MACD | MACD : | 2.1 |
Signal : | 2.1 |
| %K %D | K(14,3) : | 72.5 |
D(3) : | 85.7 |
| RSI | RSI(14): 56.7 |
|||
| 52-week | High : | 52.83 | Low : | 14.1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RAPP ] has closed above bottom band by 47.8%. Bollinger Bands are 16.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 50.73 - 51 | 51 - 51.23 |
| Low: | 47.66 - 48 | 48 - 48.28 |
| Close: | 48.26 - 48.78 | 48.78 - 49.21 |
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Wed, 26 Aug 2026
Rapport Therapeutics CEO Abraham Ceesay Sells 18,921 Shares Under Rule 10b5-1 Plan - Kalkine Media
Mon, 24 Aug 2026
Rapport Therapeutics (RAPP) officer flags $553K stock sale plan - Stock Titan
Mon, 24 Aug 2026
Rapport (NASDAQ: RAPP) insider lines up stock sale after August plan trades - Stock Titan
Wed, 19 Aug 2026
Rapport Therapeutics (NASDAQ: RAPP) plans insider sale of 2,092 shares - Stock Titan
Wed, 15 Jul 2026
Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock - Investing.com
Thu, 25 Jun 2026
RAPP Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 108.7 (%) |
| Shares Short | 2,250 (K) |
| Shares Short P.Month | 2,260 (K) |
| EPS | -3.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.81 |
| Profit Margin | 0 % |
| Operating Margin | -767.6 % |
| Return on Assets (ttm) | -25.8 % |
| Return on Equity (ttm) | -40 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.46 |
| Sales Per Share | 0.41 |
| EBITDA (p.s.) | -3.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -97 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -16.1 |
| PEG Ratio | 0 |
| Price to Book value | 5.52 |
| Price to Sales | 116.99 |
| Price to Cash Flow | -24.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|